###### Key questions

What is already known about this subject?
=========================================

-   Iron deficiency adversely impacts functional status, heart failure hospitalisation and mortality in heart failure with reduced ejection fraction; however, its role in heart failure with preserved ejection fraction (HFpEF) is less clear.

What does this study add?
=========================

-   This study synthesises the existing evidence on iron deficiency in HFpEF and highlights a high prevalence of iron deficiency in HFpEF, affecting functional status in this population.

How might this impact on clinical practice?
===========================================

-   The findings of this review inform the clinician of the importance of testing for iron deficiency in HFpEF and is of particular relevance in anticipation of the results of the FAIR-HFpEF study.

Introduction {#s1}
============

Iron deficiency (ID) is a common comorbidity in hospital inpatients, affecting over half of elderly inpatients with a complex comorbidity burden[@R1]; and in the heart failure population, affecting approximately 50% of patients with heart failure with reduced or preserved ejection fraction.[@R2] Heart failure may generate ID through multiple mechanisms. Initially, ID is thought to be due to a rise in the regulatory protein hepcidin, which prevents the release of iron from enterocytes and the reticuloendothelial system, and which may be increased in the setting of systemic inflammation.[@R3] With more advanced heart failure, however, intestinal dysfunction, with mucosal oedema, reduced gastric emptying and modified intestinal motility; reduced dietary consumption of iron-rich foods with anorexia; and increased blood loss due to anticoagulants and gastric ulceration may play more significant roles.[@R3]

The relationship between heart failure and ID is complex, however, as ID worsens heart failure prognosis and may be involved in myocardial remodelling. Studies in patients with heart failure with reduced ejection fraction (HFrEF) indicate significantly higher mortality,[@R5] poorer exercise capacity as determined by VO~2~ max,[@R6] lower endurance capacity and cardiac work productivity,[@R7] and lower quality of life[@R8] in ID compared with iron-replete patients. The mechanisms behind this are likely related to the role of iron in the metabolism of cells with high energy demands, such as cardiomyocytes and skeletal muscle[@R9]; due to its role in mitochondrial function, oxygen storage and metabolism.[@R9]

Treatment of ID has largely centred around intravenous iron therapy in the HFrEF population due to the reduced absorption of oral iron in these patients and increased hepcidin levels, rendering oral therapy ineffective.[@R3] Intravenous iron therapy increases quality of life,[@R11] regardless of whether patients are anaemic or not; improves functional outcomes such as dyspnoea score and 6 min walk test; and reduces both hospitalisation rates and heart failure--related mortality; all without an increase in adverse events.[@R13] However, the majority of studies and particularly meta-analyses have exclusively included patients with HFrEF.[@R11] This is significant, given the emerging epidemic of heart failure with preserved ejection fraction (HFpEF)[@R15]; a population plagued by exercise intolerance and poor quality of life, and who have similar mortality rates to HFrEF.[@R16]

It is certainly plausible that ID may play a role in the pathogenesis and prognosis of HFpEF, and that treatment with intravenous iron therapy may therefore improve outcomes including functional status, hospitalisation and death. Studies to date investigating the role of iron deficiency in HFpEF have not reached a consensus on its prevalence and impact on heart failure outcomes. Therefore, the objective of this systematic review and meta-analysis is to estimate the prevalence of ID in patients with HFpEF. Furthermore, this review aims to detail the impact that ID has on functional outcomes, such as exercise tolerance and quality of life, along with hard clinical endpoints such as hospitalisation and mortality. This is the first review to our knowledge addressing these questions and plays an important role in outlining the significance of ID in HFpEF.

Methods {#s2}
=======

Protocol and registration {#s2-1}
-------------------------

Our review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews. The supporting PRISMA checklist is available as online [supplementary information](#SP1){ref-type="supplementary-material"}. The PROSPERO registered protocol number is 42017069896.
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Database and search strategies {#s2-2}
------------------------------

We conducted a comprehensive literature search for papers using a predetermined search strategy, described in online [supplemental materials](#SP1){ref-type="supplementary-material"}. The search strategy was developed in collaboration between the lead author and medical librarian. We conducted the search in English in the following electronic databases: EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effect, Ovid MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE, CINAHL and Web Of Science Core Collection. Reference lists of key papers identified within the literature search were also reviewed.

Inclusion criteria {#s2-3}
------------------

Included studies evaluated the prevalence and impact of ID in patients with HFpEF, and the inclusion criteria, along with criteria for the diagnosis of HFpEF and ID, are detailed in online [supplemental materials](#SP1){ref-type="supplementary-material"}.

Study selection and data extraction {#s2-4}
-----------------------------------

Citations from search results were screened separately and data collected in duplicate by JLW and ALB, as further detailed in online [supplemental materials](#SP1){ref-type="supplementary-material"}.

Quality assessment {#s2-5}
------------------

A quality assessment was conducted on all papers by ALB and JLW at the time of data extraction, as further detailed in online [supplemental materials](#SP1){ref-type="supplementary-material"}.

Synthesis of results {#s2-6}
--------------------

Meta analysis was performed for the prevalence of ID in HFpEF using the 'meta' package for R statistics using the inverse variance method. We used a random-effects meta-analysis as the studies were conducted in a range of settings and populations. Statistical heterogeneity was assessed using the I^2^ statistic. Meta analysis of prevalence was repeated for functional and absolute iron deficiency separately.

Due to the considerable heterogeneity of included studies with regard to their study design and outcome measures, including measurement of effect, meta-analysis was not possible for functional outcomes or hospitalisation and mortality outcomes according to ID in HFpEF. Instead, data were extracted into tables, categorised by outcome category and results described.

Results {#s3}
=======

Study selection {#s3-1}
---------------

The database search retrieved 8008 citations. After the removal of 1713 duplicates and 166 animal studies, there were 6129 citations that underwent title and abstract screening. Of this, 38 studies underwent full-text screening, and 15 met the inclusion criteria. The primary reason that studies were excluded at the time of full-text review was that data were not stratified according to ejection fraction, and therefore the cohort with HFpEF could not be assessed. The study selection process is further detailed in [figure 1](#F1){ref-type="fig"}.

![PRISMA flow chart.](openhrt-2019-001012f01){#F1}

Study characteristics {#s3-2}
---------------------

Included studies were published between 2013 and 2017, reflecting our inclusion of those that met the 2012 European Society of Cardiology (ESC) guidelines criteria for the diagnosis of HFpEF, with an EF ≥50%. The total number of patients with HFpEF from these 15 studies was 1877. Studies reporting the percentage of women in their cohorts ranged from 42% to 69.8% women. In those reporting average age of participants, the average age ranged from 53±8 to 79.8±8 years.

Quality assessment of included studies {#s3-3}
--------------------------------------

[Tables 1 and 2](#T1 T2){ref-type="table"} show the quality of the studies as evaluated using the Newcastle-Ottawa Scale. A summary of the quality assessment is detailed in online supplemental materials. Overall, the Grade quality of evidence was very low (⊗ΟΟΟ), as a result of being based on a relatively small number of observational studies with substantial heterogeneity.

###### 

Newcastle-Ottawa score for included cross-sectional studies

  Study                  Representativeness of the sample   Sample size   Non-respondents   Ascertainment of the exposure   Comparability of subjects in different outcome groups   Assessment of the outcome   Statistical test is appropriate   Total score   Funding source
  ---------------------- ---------------------------------- ------------- ----------------- ------------------------------- ------------------------------------------------------- --------------------------- --------------------------------- ------------- ------------------------------------------------------
  Araujo[@R29]           1                                  0             0                 1                               0                                                       NA                          1                                 3             No description
  Barandarian[@R40]      1                                  0             0                 0                               0                                                       NA                          1                                 2             No description
  Bekfani[@R41]          1                                  0             0                 1                               0                                                       1                           1                                 4             No description
  Kasner[@R19]           0                                  0             0                 1                               1                                                       1                           1                                 4             Supported by the EC, FP7-Health-2010, MEDIA (261409)
  Lainscak[@R42]         1                                  0             0                 1                               0                                                       NA                          1                                 4             No description
  Nieto Sandoval[@R28]   1                                  0             0                 0                               0                                                       1                           0                                 2             No description
  Nunez[@R22]            1                                  0             0                 0                               1                                                       1                           1                                 4             Sociedad Española de Cardiología
  Orynchak[@R23]         1                                  0             0                 0                               0                                                       1                           1                                 3             No description
  Yeo[@R43]              1                                  0             0                 1                               0                                                       NA                          1                                 4             Vifor Pharma
  Yeo[@R24]              1                                  0             0                 1                               0                                                       1                           1                                 4             No description

NA, not available.

###### 

Newcastle-Ottawa score and funding source for included cohort studies

  Study              Representativeness of the exposed cohort   Selection of the non-exposed cohort   Ascertainment of exposure   Demonstration that outcome of interest was not present at start of study   Comparability of cohorts on the basis of the design or analysis   Assessment of outcome   Was follow-up long enough for outcomes to occur?   Total score   Funding source
  ------------------ ------------------------------------------ ------------------------------------- --------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------- -------------------------------------------------- ------------- ----------------
  Borut Jug[@R25]    1                                          1                                     1                           1                                                                          1                                                                 1                       1                                                  7             No description
  Carmo[@R44]        1                                          1                                     1                           1                                                                          0                                                                 NA                      NA                                                 4             No description
  Fitzsimons[@R26]   1                                          1                                     1                           1                                                                          0                                                                 1                       1                                                  \*            No description
  Martens[@R20]      1                                          1                                     1                           1                                                                          1                                                                 1                       1                                                  7             Vifor Pharma

NA, not available.

Definition of iron deficiency {#s3-4}
-----------------------------

The majority of studies used a definition of iron deficiency as a ferritin level \<100 µg/L or 100--300 µg/L with a transferrin saturation \<20%; however, three studies (Nieto Sandoval *et al*, Nunez *et al*, Orynchak *et al*) did not explicitly outline how iron deficiency was defined.

Prevalence of ID in HFpEF {#s3-5}
-------------------------

The pooled prevalence of ID in HFpEF is shown in [figure 2](#F2){ref-type="fig"}. The pooled results of 11 studies suggested a prevalence of iron deficiency in HFpEF of 59% (95% CI 52%--65%, I^2^=80%; 1424 participants). The prevalence of functional and absolute ID are represented in [figures 3 and 4](#F3 F4){ref-type="fig"}, respectively. The prevalence of functional ID was 34% (95% CI 18% to 54%, I^2^=96%, 832 participants) and absolute ID 30% (95% CI 17% to 46%, I^2^=93%, 678 participants). There was considerable heterogeneity across all analyses, particularly in sub-analyses of functional and absolute ID. In the meta-analysis of overall prevalence of ID, removal of the study by Araujo *et al* significantly reduced the heterogeneity to 47% (prevalence 61%, 95% CI 57% to 65%).

![Pooled prevalence of iron deficiency in patients with HFpEF.](openhrt-2019-001012f02){#F2}

![Meta-analysis of functional iron deficiency prevalence.](openhrt-2019-001012f03){#F3}

![Meta-analysis of absolute iron deficiency prevalence.](openhrt-2019-001012f04){#F4}

Outcomes of ID in HFpEF {#s3-6}
-----------------------

A range of different outcome measures were employed across the included studies, as detailed in [table 3](#T3){ref-type="table"}.

###### 

Prevalence and outcomes of iron deficiency (summary of findings table)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                           Sample size (HFpEF)   \% women   Ejection fraction cut-off for HFpEF   Average age (years)   Prevalence of iron deficiency   Outcome measures   Outcome                                             
  ------------------------------- --------------------- ---------- ------------------------------------- --------------------- ------------------------------- ------------------ --------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Araujo, 2015[@R29]              117                   69.8       ≥50%                                  74.95±11.8            31.4%                           --                 --        Nil (prevalence only)                     NA

  Barandiaran, 2017[@R40]         115                   67.8       ≥50%                                  --                    50%                             --                 --        Nil (prevalence only)                     NA

  Bekfani, 2015[@R41]             233                   --         ≥50%                                  71±9                  56%                             46.8%              9.2%      Peak VO~2~\                               Ferritin positively correlated with peak VO~2~, r=0.28, p=0.03\
                                                                                                                                                                                            Exercise time\                            Exercise time negatively correlated with ferritin r=0.31, p=0.01\
                                                                                                                                                                                            6MWT\                                     416±125 m IR, 367±138 m ID, p=0.05\
                                                                                                                                                                                            EQ-5D questionnaire                       Ferritin correlated positively with distance walked r=0.24, p=0.01\
                                                                                                                                                                                                                                      19062±4704 IR, 16373±5304 ID, p\<0.05

  Borut Jug, 2016[@R25]           220                   --         Not described                         --                    --                              --                 --        Death or hospitalisation (composite)      OR 1.88 (0.917--3.861), p=0.085 for iron-deficient patients\
                                                                                                                                                                                                                                      Adjusted for age, gender, NYHA class, ischaemic aetiology, natriuretic peptides, renal function, anaemia

  Carmo, 2014[@R44]               47                    --         Not described                         78.9±9.2              72.3%                           --                 --        Nil (prevalence only)                     NA

  Fitzsimons\*, 2015/2016[@R26]   280                   45%        ≥50%                                  73.8                  64%                             23%                41%       Death                                     HR 0.98 (0.53--1.81), p=0.95 for iron-deficient patients

  Kasner, 2013[@R19]              26                    42%        Not described                         55±8.5                58%                             35%                23%       NT-proBNP levels (pg/mL)\                 NT-proBNP 192±199 ID vs 169±109, p=0.095\
                                                                                                                                                                                            VO~2~ (mL/min/kg)\                        17±1.5 ID vs 18±3 IR, p=0.93\
                                                                                                                                                                                            Exercise performance (W)                  102±25 ID vs 121±50 IR, p=0.49\
                                                                                                                                                                                                                                      Analyses were not adjusted but patients had similar baseline characteristics

  Lainscak, 2015[@R42]            207                   42%        ≥50%                                  71±12                 56%                             --                 --        Nil (prevalence only in HFpEF)            NA

  Martens, 2017[@R20]             72                    --         ≥50%                                  --                    64%                             --                 --        VO~2~ (mL/min/kg)\                        16±5 IR, 9±2 ID, p\<0.001\
                                                                                                                                                                                            All-cause mortality and hospitalisation   Significantly higher in ID vs IR, p=0.001, adjusted for age, gender, implantable cardioverter defibrillator use, CRT use, ischaemic aetiology, medication use and baseline LVEF

  Nieto Sandoval, 2017[@R28]      139                   65.3%      ≥50%                                  79.8±8                67%                             19%                48%       Death                                     Higher ferritin associated with increased mortality in HFpEF (statistics not quoted)

  Nunez, 2016[@R22]               40                    55%        ≥50%                                  74±5.5                70%                             --                 --        VO~2~                                     Log VO~2~ correlated with TSAT (r=0.46, p=0.003) and ferritin (r=0.30, p=0.048) in HFpEF\
                                                                                                                                                                                                                                      Adjusted for gender, HR, NT-proBNP, eGFR, E/e′, Hb, TAPSE

  Orynchak, 2014[@R23]            79                    65%        ≥50%                                  53±8                  --                              --                 --        NYHA class                                NYHA class II/III associated with lower serum iron, ferritin and transferrin regardless of anaemia status

  Yeo, 2014[@R43]                 154                   --         ≥50%                                  --                    --                              --                 61%       Nil (prevalence only for HFpEF)           NA

  Yeo, 2014†[@R24]                148                   --         ≥50%                                  --                    60.1%                           --                 --        MLHFQ\                                    Patients with FID had worse MLHFQ compared with IR (28 vs 36, p\<0.05)\
                                                                                                                                                                                            NYHA functional class                     Patients with FID had no difference in NYHA class compared with IR (1.85 vs 2, p=0.16)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Fitzsimons *et al* had two papers reporting on the same cohort, therefore information on this cohort was gathered from the two publications and reported as the same population in our summary of findings table.

†Yeo *et al* did not use a standard definition of iron deficiency: they defined iron deficiency as transferrin saturation \<20%, without any criteria for ferritin.

CRT, cardiac resynchronisation therapy; FID, functional iron deficiency; HFpEF, heart failure with preserved ejection fraction; ID, iron deficient; IR, iron replete; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; 6MWT, 6 min walk test; NA, not available; NYHA, New York Heart Association; TAPSE, tricuspid annular plane systolic excursion; TSAT, transferrin saturation.

The most common outcome measure was oxygen consumption at peak exercise (VO~2~ max), which was used in four studies. The VO~2~ max (and exercise time achieved) did not differ between ID and iron-replete groups in the study by Kasner *et al* (17±1.5 mL/min/kg ID vs 18±3 mL/min/kg iron replete, p=0.93),[@R19] whereas it was significantly higher in iron-replete patients in the study by Martens *et al* (16±5 mL/min/kg iron replete, 9±2 mL/min/kg ID, p\<0.001).[@R20] Two studies, by Bekfani *et al* and Nunez *et al*, found a significant positive correlation between indices of iron stores and VO~2~ max. Bekfani *et al* showed a positive correlation between ferritin and peak VO~2~ (r=0.28, p=0.03)[@R21] along with a positive correlation between ferritin and exercise time (r=0.31, p=0.01); and Nunez *et al* found positive correlations between both transferrin saturation (r=0.46, p=0.003) and ferritin (r=0.30, p=0.048) with log VO~2~ max,[@R22] adjusting for gender, heart rate, NT-proBNP, glomerular filtration rate, E/e′, haemoglobin and tricuspid annular plane systolic excursion.

Another measure of exercise tolerance and symptoms employed was the New York Heart Association (NYHA) functional class. Orynchak *et al* found that worsening NYHA class was associated with lower serum iron, ferritin and transferrin saturation, regardless of anaemia status.[@R23] Conversely, Yeo *et al* found that patients with functional ID had no difference in NYHA class compared with iron-replete patients (1.85 vs 2, p=0.16).[@R24] The 6 min walk test (6MWT) was assessed in one study, Bekfani *et al*, finding a shorter distance covered in ID patients (416±125 m iron replete vs 367±138 m ID, p=0.05) and that ferritin correlated positively with distance walked (r=0.24, p=0.01).[@R21]

Two studies assessed the impact of iron deficiency on patient-reported quality of life. Bekfani *et al* used the EQ-5D questionnaire and found a significantly lower quality of life in ID patients (19 062±4704 iron replete vs 16 373±5304 ID, p\<0.05).[@R21] Similarly, Yeo *et al* used the Minnesota Living With Heart Failure Questionnaire (MLWHFQ), finding a lower score in ID patients (ID 28 vs iron replete 36, p\<0.05), indicative of poorer quality of life.[@R24]

The composite outcomes of death and hospitalisation were frequently used. Martens *et al* assessed all-cause mortality and hospitalisation, with significantly higher rates of this composite outcome in ID patients (OR not detailed, p=0.001).[@R20] However, Borut Jug *et al* also analysed differences in composite death and rehospitalisation, which was not significantly different between ID and iron-replete patients (OR 1.88, 95% CI 0.917 to 3.861, p=0.085 for ID patients).[@R25] Fitzsimons *et al* investigated the outcome of death between ID and iron-replete patients, finding no significant difference (HR 0.98, 95% CI 0.53 to 1.81, p=0.95 for ID patients).[@R26] In fact, Nieto Sandoval *et al* reported a *positive* correlation between ferritin and mortality; however, statistics were not quoted.[@R28]

Kasner *et al* investigated differences in NT-proBNP between iron-replete and ID patients, finding no difference (192±199 ID vs iron replete 169±109, p=0.095).[@R19]

Discussion {#s4}
==========

In this systematic review, 15 studies with 1877 patients with HFpEF in total were included. We performed a meta-analysis of the prevalence of ID in HFpEF including 1424 patients, highlighting a high prevalence of 59% in this population. In the qualitative analysis of the included studies in this systematic review, the majority demonstrated an association between ID and poorer functional capacity as determined by VO~2~ max, NYHA class, 6MWT and quality of life. Conversely, three of the four studies assessing the impact of ID on death and rehospitalisation in HFpEF failed to find an association.

The prevalence of ID in HFpEF of 59% is higher than the prevalence of ID in patients with heart failure overall in an international pooled analysis, at 50%,[@R2] suggesting that ID is even more common in patients with HFpEF than patients with HFrEF. There was substantial heterogeneity in the estimate of ID prevalence, with an I^2^ of 80%; however, this improved significantly to 47% after removal of a single study[@R29] that reported a much lower prevalence than the remaining 10 studies. This suggests that we can be reasonably confident that the prevalence of ID in HFpEF is approximately 60%. The high prevalence of ID underscores the importance of performing iron studies in patients with HFpEF and HFrEF alike.

ID had a deleterious impact on exercise tolerance and functional capacity in the majority of studies included in our qualitative review. Three out of four studies found a relationship between ID and worse VO~2~ max,[@R20] with similar findings of reduced exercise time with ID. VO~2~ max is central to exercise tolerance and is markedly reduced in patients with HFpEF for whom impaired exercise capacity is a cardinal feature.[@R30] There are numerous sequences in the oxygen consumption pathway, which is a complex interaction of respiratory, cardiovascular, haematological and skeletal muscle components.[@R30] ID can affect multiple aspects of this pathway, including reducing oxygen storage and oxygen-carrying capacity, and causing mitochondrial dysfunction in both heart and skeletal muscle, resulting in reduced energetic efficiency and anaerobic metabolism.[@R10]

Furthermore, ID may have direct impacts on myocardial remodelling. Animal studies have indicated that severe ID can result in significant cardiac remodelling with left ventricular hypertrophy, fibrosis and diastolic dysfunction.[@R31] This is yet to be established in patients with HFpEF; however, there is evidence in the HFrEF cohort, in a study of cardiac resynchronisation therapy (CRT). Patients with HFrEF were followed up for 38±22 months following CRT implantation, and 56% of patients who were iron deficient at the time of initiation of CRT therapy experienced significantly less improvement in left ventricular end-diastolic diameter and less of an increase in left ventricular ejection fraction than those who were iron replete. In addition to these differences in remodelling, ID predicted more heart failure admissions and higher all-cause mortality, along with less symptomatic improvement with CRT.[@R32] This could suggest a role for ID in mediating myocardial remodelling.

This review also identified consistent reductions in quality of life in the two studies that included this as an outcome measure, using the EQ-5D[@R21] and MLWHFQ[@R24] questionnaires. A reduced quality of life in patients with HFpEF who are iron deficient could be due to the aforementioned association with reduced exercise tolerance, limiting patients' capacity to complete activities of daily living and engage in leisure activities. Furthermore, ID has strong associations with fatigue, which is a likely contributor to this finding. Indeed, the CONFIRM-HF study of intravenous iron treatment in patients with HFrEF found an improvement in fatigue score with the correction of ID with ferric carboxymaltose.[@R33]

In patients with HFrEF, ID is associated with significantly poorer survival[@R34]; however, clinical trials of intravenous ferric carboxymaltose therapy for ID have not demonstrated a reduction in mortality in patients with HFrEF.[@R33] While the study by Martens *et al* demonstrated a significantly higher composite outcome of hospitalisation and mortality in ID patients with HFpEF,[@R20] the remaining three studies investigating this relationship did not substantiate this; in fact, the study by Nieto Sandoval *et al* found that survival worsened with increasing ferritin.[@R25] This may suggest that ID plays a more important role in functional outcomes, rather than impacting hospitalisation and survival. Despite the aforementioned relationship between ID and survival in HFrEF, this parallels what has been found in trials of intravenous ferric carboxymaltose in HFrEF.

Exercise intolerance is central to HFpEF, highlighted by the improved diagnostic acumen of stress echocardiography and exercise invasive haemodynamics for HFpEF relative to resting investigations.[@R36] Exercise intolerance often precedes the development of overt HFpEF and episodes of decompensated heart failure, and therefore the greatest potential impact of ID may be in those patients with earlier stages of HFpEF, worsening symptoms and affecting functional outcomes rather than hospitalisation for heart failure or mortality in the later stages of the disease. Interestingly, patients with HFpEF are more likely to die of non-cardiac causes than patients with HFrEF,[@R38] which could blunt the effect that ID has on mortality in HFpEF.

This review establishes a clear role for ID in worsening exercise tolerance, functional outcomes and quality of life in patients with HFpEF. It carries implications for the potential therapeutic benefit of intravenous iron treatment in patients with HFpEF, which could foreseeably significantly improve HFpEF patients' quality of life and function. This paves the way for the FAIR-HFpEF study, which is currently recruiting (NCT03074591).[@R39] Based on the results of this systematic review, it is less clear whether intravenous ferric carboxymaltose will have an impact on survival and hospitalisation for heart failure; however, functional improvements may even be preferable in this predominantly elderly population.

The strength of our study is that it is the first to comprehensively synthesise the evidence surrounding the impact of ID on outcomes in patients with HFpEF. Furthermore, this systematic review and meta-analysis was performed in accordance with PRISMA recommendations, with independent reviewers for double data extraction and analysis. Therefore, the methodology of this study is sound and represents the best possible synthesis of the available literature.

There are several limitations of this study. Due to a lack of consistency in outcome variables reported by studies meeting our inclusion criteria, we were unable to perform a quantitative synthesis of any of the outcomes associated with ID in patients with HFpEF. A meta-analysis would have strengthened our conclusions regarding the impact of ID on exercise tolerance and functional outcomes. Part of the reason behind this variability in outcome measures was the small number of studies included in this systematic review, which was a result of the strict inclusion criteria to ensure that only patients with HFpEF according to the latest diagnostic criteria were included.

In addition, there was substantial heterogeneity in our findings, particularly in the meta-analysis of the prevalence of ID. This was further amplified when assessing the prevalence of functional and absolute ID separately, rendering these findings difficult to interpret. Sources of heterogeneity included considerable differences in the populations studied, along with different research methodologies. Furthermore, only four studies reported similar baseline characteristics or controlled for factors such as age, gender, ischaemic aetiology, natriuretic peptides, renal function and anaemia.[@R19] Heart failure itself causes ID, as do comorbid conditions such as chronic renal impairment, and therefore ID could be in part reflective of patients with a more severe HFpEF phenotype and concurrent comorbidities. It is important to interpret our findings with the consideration that some of the associations between ID and functional outcome may have been mediated by these confounders.

Conclusion {#s5}
==========

This systematic review analysed data from 1877 patients with HFpEF and found that ID is highly prevalent in this HFpEF population. Furthermore, the majority of studies included demonstrated a detrimental influence of ID on VO~2~, NYHA class, 6MWT and health-related quality of life. These findings are suggestive of an important role of ID in HFpEF, indicating that it has a similar impact to that in HFrEF.
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